In In re Entresto (Sacubitril/Valsartan) Patent Litigation, Judge Richard G. Andrews of the U.S. District Court for the District of Delaware granted MSN Pharmaceuticals Inc. a victory on noninfringement of U.S. Patent No....more
7/16/2025
/ Abbreviated New Drug Application (ANDA) ,
Adverse Inference Instructions ,
Claim Construction ,
Generic Drugs ,
Healthcare ,
Intellectual Property Protection ,
Life Sciences ,
Novartis ,
Patent Infringement ,
Patent Litigation ,
Patents ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Prescription Drugs
On May 18, 2023, the U.S. Supreme Court handed down a unanimous decision in the much-anticipated Amgen Inc. v. Sanofi case. See 598 U.S. ___, No. 21-757, 2023 WL 3511533 (May 18, 2023). In so doing, the Court maintained the...more
The U.S. Court of Appeals for the Federal Circuit issued two significant decisions last year that affect the protection of biotechnology through the use of functional genus claims — Amgen Inc. v. Sanofi and Juno Therapeutics...more